Other markers expressed in tumor cells from a minority of neuroblastic tumor samples included: CD57 positive in 5/43 samples (11.6%), CD271 expressed at low levels in 7/43 samples (16%), and CD117 that was positive in 4/43 samples (9.3%). This evidence concerns the gene B3GAT1 and neoplasm.